Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.

Kirchgesner J, Nyboe Andersen N, Carrat F, Jess T, Beaugerie L; BERENICE study group.

Gut. 2019 Aug 24. pii: gutjnl-2019-318932. doi: 10.1136/gutjnl-2019-318932. [Epub ahead of print]

PMID:
31446428
2.

Correction: Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population.

Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; T2D-GENES Consortium, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ.

PLoS Genet. 2019 May 30;15(5):e1008190. doi: 10.1371/journal.pgen.1008190. eCollection 2019 May.

3.

Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia.

Kirchgesner J, Svrcek M, Le Gall G, Landman C, Dray X, Bourrier A, Nion-Larmurier I, Hoyeau N, Sokol H, Seksik P, Cosnes J, Fléjou JF, Beaugerie L; Saint-Antoine Inflammatory Bowel Disease Network.

Clin Gastroenterol Hepatol. 2019 May 11. pii: S1542-3565(19)30511-7. doi: 10.1016/j.cgh.2019.05.002. [Epub ahead of print]

PMID:
31085339
4.

Genetic effects on the commensal microbiota in inflammatory bowel disease patients.

Aschard H, Laville V, Tchetgen ET, Knights D, Imhann F, Seksik P, Zaitlen N, Silverberg MS, Cosnes J, Weersma RK, Xavier R, Beaugerie L, Skurnik D, Sokol H.

PLoS Genet. 2019 Mar 8;15(3):e1008018. doi: 10.1371/journal.pgen.1008018. eCollection 2019 Mar.

5.

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.

Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC, Beaugerie L, Bewshea CM, Cole AT, Cummings FR, Daly MJ, Ellul P, Fedorak RN, Festen EAM, Florin TH, Gaya DR, Halfvarson J, Hart AL, Heerasing NM, Hendy P, Irving PM, Jones SE, Koskela J, Lindsay JO, Mansfield JC, McGovern D, Parkes M, Pollok RCG, Ramakrishnan S, Rampton DS, Rivas MA, Russell RK, Schultz M, Sebastian S, Seksik P, Singh A, So K, Sokol H, Subramaniam K, Todd A, Annese V, Weersma RK, Xavier R, Ward R, Weedon MN, Goodhand JR, Kennedy NA, Ahmad T; IBD Pharmacogenetics Study Group.

JAMA. 2019 Feb 26;321(8):773-785. doi: 10.1001/jama.2019.0709. Erratum in: JAMA. 2019 Apr 23;321(16):1636.

6.

Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria.

Battipaglia G, Malard F, Rubio MT, Ruggeri A, Mamez AC, Brissot E, Giannotti F, Dulery R, Joly AC, Baylatry MT, Kossmann MJ, Tankovic J, Beaugerie L, Sokol H, Mohty M.

Haematologica. 2019 Aug;104(8):1682-1688. doi: 10.3324/haematol.2018.198549. Epub 2019 Feb 7.

7.

Inhibitory Effect of Ursodeoxycholic Acid on Clostridium difficile Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans.

Palmieri LJ, Rainteau D, Sokol H, Beaugerie L, Dior M, Coffin B, Humbert L, Eguether T, Bado A, Hoys S, Janoir C, Duboc H.

Front Microbiol. 2018 Nov 22;9:2849. doi: 10.3389/fmicb.2018.02849. eCollection 2018.

8.

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.

Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D.

Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24.

PMID:
30472651
9.

Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency.

Sokol H, Mahlaoui N, Aguilar C, Bach P, Join-Lambert O, Garraffo A, Seksik P, Danion F, Jegou S, Straube M, Lenoir C, Neven B, Moshous D, Blanche S, Pigneur B, Goulet O, Ruemmele F, Suarez F, Beaugerie L, Pannier S, Mazingue F, Lortholary O, Galicier L, Picard C, de Saint Basile G, Latour S, Fischer A.

J Allergy Clin Immunol. 2019 Feb;143(2):775-778.e6. doi: 10.1016/j.jaci.2018.09.021. Epub 2018 Oct 10. No abstract available.

PMID:
30312711
10.

Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease-Related Colorectal Neoplastic Lesions: The Role of Inflammation.

Svrcek M, Borralho Nunes P, Villanacci V, Beaugerie L, Rogler G, De Hertogh G, Tripathi M, Feakins R; H-ECCO group.

J Crohns Colitis. 2018 Nov 28;12(12):1486-1498. doi: 10.1093/ecco-jcc/jjy132. Review.

PMID:
30202940
11.

Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease.

Le Gall G, Kirchgesner J, Bejaoui M, Landman C, Nion-Larmurier I, Bourrier A, Sokol H, Seksik P, Beaugerie L.

PLoS One. 2018 Aug 31;13(8):e0201991. doi: 10.1371/journal.pone.0201991. eCollection 2018.

12.

Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota.

Landman C, Grill JP, Mallet JM, Marteau P, Humbert L, Le Balc'h E, Maubert MA, Perez K, Chaara W, Brot L, Beaugerie L, Sokol H, Thenet S, Rainteau D, Seksik P, Quévrain E; Saint Antoine IBD Network.

PLoS One. 2018 Aug 29;13(8):e0202587. doi: 10.1371/journal.pone.0202587. eCollection 2018.

13.

Colorectal cancer prevention in patients with ulcerative colitis.

Lopez A, Pouillon L, Beaugerie L, Danese S, Peyrin-Biroulet L.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:103-109. doi: 10.1016/j.bpg.2018.05.010. Epub 2018 May 16. Review.

PMID:
30060933
14.

Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases.

Beaugerie L, Kirchgesner J.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):370-379. doi: 10.1016/j.cgh.2018.07.013. Epub 2018 Jul 18. Review.

PMID:
30031174
15.

Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study.

de Risi-Pugliese T, Seksik P, Bouaziz JD, Chasset F, Moguelet P, Gornet JM, Bourrier A, Amiot A, Beaugerie L, Francès C, Guégan S; Ustekinumab–Crohn's Disease–Neutrophilic Dermatosis Study Group.

J Am Acad Dermatol. 2019 Mar;80(3):781-784. doi: 10.1016/j.jaad.2018.06.065. Epub 2018 Jul 10. No abstract available.

PMID:
30003991
16.

Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population.

Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; T2D-GENES Consortium, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ.

PLoS Genet. 2018 May 24;14(5):e1007329. doi: 10.1371/journal.pgen.1007329. eCollection 2018 May. Erratum in: PLoS Genet. 2019 May 30;15(5):e1008190.

17.

Differences in epidemiological features between ulcerative colitis and Crohn's disease: The early life-programmed versus late dysbiosis hypothesis.

Beaugerie L, Langholz E, Nyboe-Andersen N, Pigneur B, Sokol H; ECCO Epicom.

Med Hypotheses. 2018 Jun;115:19-21. doi: 10.1016/j.mehy.2018.03.009. Epub 2018 Mar 23.

18.

Postoperative Morbidity Risks Following Ileocolic Resection for Crohn's Disease Treated With Anti-TNF Alpha Therapy: A Retrospective Study of 360 Patients.

Jouvin I, Lefevre JH, Creavin B, Pitel S, Chafai N, Tiret E, Beaugerie L, Parc Y; Saint-Antoine IBD Network.

Inflamm Bowel Dis. 2018 Jan 18;24(2):422-432. doi: 10.1093/ibd/izx036.

PMID:
29361093
19.

Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.

de Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel JF, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF.

J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181. Review.

PMID:
29293971
20.

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease.

Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabaté JM, Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M; Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France Study Group.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):892-899.e2. doi: 10.1016/j.cgh.2017.11.041. Epub 2017 Dec 2.

PMID:
29199142
21.

Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.

Martineau C, Flourié B, Wils P, Vaysse T, Altwegg R, Buisson A, Amiot A, Pineton de Chambrun G, Abitbol V, Fumery M, Hébuterne X, Viennot S, Laharie D, Beaugerie L, Nancey S, Sokol H; Goli-Crohn Study Group.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1077-1084. doi: 10.1111/apt.14371. Epub 2017 Oct 13.

22.

Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection.

Sokol H, Jegou S, McQuitty C, Straub M, Leducq V, Landman C, Kirchgesner J, Le Gall G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Richard ML, Beaugerie L.

Gut Microbes. 2018 Jan 2;9(1):55-60. doi: 10.1080/19490976.2017.1361092. Epub 2017 Sep 21.

23.

Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.

Kirchgesner J, Beaugerie L, Carrat F, Andersen NN, Jess T, Schwarzinger M; BERENICE study group.

Gut. 2018 Jul;67(7):1261-1268. doi: 10.1136/gutjnl-2017-314015. Epub 2017 Jun 24.

PMID:
28647686
24.

Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives.

Wisniewski A, Fléjou JF, Siproudhis L, Abramowitz L, Svrcek M, Beaugerie L.

J Crohns Colitis. 2017 Aug 1;11(8):1011-1018. doi: 10.1093/ecco-jcc/jjx035. Review.

PMID:
28379306
25.

Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study.

Sokol H, Lalande V, Landman C, Bourrier A, Nion-Larmurier I, Rajca S, Kirchgesner J, Seksik P, Cosnes J, Barbut F, Beaugerie L.

Dig Liver Dis. 2017 Jun;49(6):643-646. doi: 10.1016/j.dld.2017.01.162. Epub 2017 Jan 30.

PMID:
28215602
26.

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases.

Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bouguen G, Bourreille A, Ferrante M, Franchimont D, Frost K, Hebuterne X, Marshall JK, OʼShea C, Rosenfeld G, Williams C, Peyrin-Biroulet L.

Inflamm Bowel Dis. 2017 Mar;23(3):333-340. doi: 10.1097/MIB.0000000000001033.

27.

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L; CESAME Study Group.

Aliment Pharmacol Ther. 2017 Feb;45(4):533-541. doi: 10.1111/apt.13897. Epub 2016 Dec 19.

28.

No Excess Cancer Recurrence After Immunosuppressive Drugs in a Meta-analysis of Cohorts of Patients With Immune-mediated Diseases: A Mirage Related to Propensity Bias?

Beaugerie L, Peyrin-Biroulet L.

Gastroenterology. 2017 Jan;152(1):304-306. doi: 10.1053/j.gastro.2016.08.067. Epub 2016 Nov 26. No abstract available.

PMID:
27893979
29.

Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.

Cosnes J, Sokol H, Bourrier A, Nion-Larmurier I, Wisniewski A, Landman C, Marteau P, Beaugerie L, Perez K, Seksik P.

Aliment Pharmacol Ther. 2016 Nov;44(10):1102-1113. doi: 10.1111/apt.13808. Epub 2016 Sep 26.

30.

Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients.

Williet N, Sarter H, Gower-Rousseau C, Adrianjafy C, Olympie A, Buisson A, Beaugerie L, Peyrin-Biroulet L.

J Crohns Colitis. 2017 Feb;11(2):165-174. doi: 10.1093/ecco-jcc/jjw145. Epub 2016 Aug 11.

PMID:
27516406
31.

Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis.

Kirchgesner J, Beaugerie L, Carrat F, Sokol H, Cosnes J, Schwarzinger M; BERENICE Study Group.

PLoS One. 2016 Jun 6;11(6):e0157191. doi: 10.1371/journal.pone.0157191. eCollection 2016.

32.

CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands.

Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H.

Nat Med. 2016 Jun;22(6):598-605. doi: 10.1038/nm.4102. Epub 2016 May 9.

33.

Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy.

Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, Savoye G, Lourenço N, Altwegg R, Buisson A, Cazelles-Boudier C, Racine A, Vergniol J, Laharie D; le GETAID.

Inflamm Bowel Dis. 2016 Jun;22(6):1362-9. doi: 10.1097/MIB.0000000000000741.

PMID:
26919458
34.

Fungal microbiota dysbiosis in IBD.

Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L.

Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746. Epub 2016 Feb 3.

35.

Azathioprine May Not be Associated With Development of Colorectal Tumors With Microsatellite Instability in Patients With Inflammatory Bowel Disease.

Svrcek M, Beaugerie L, Kirchgesner J, Dumont S, Muleris M, Bodo S, Dartigues P, Lascols O, Seksik P, Cosnes J, Fléjou JF, Duval A.

Am J Gastroenterol. 2016 Jan;111(1):149-51. doi: 10.1038/ajg.2015.406. No abstract available.

PMID:
26785668
36.

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group.

Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9.

37.

Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation.

Sokol H, Galperine T, Kapel N, Bourlioux P, Seksik P, Barbut F, Scanzi J, Chast F, Batista R, Joly F, Joly AC, Collignon A, Guery B, Beaugerie L; French Group of Faecal microbiota Transplantation (FGFT).

Dig Liver Dis. 2016 Mar;48(3):242-7. doi: 10.1016/j.dld.2015.08.017. Epub 2015 Sep 7.

PMID:
26433619
38.

Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.

Launay O, Abitbol V, Krivine A, Slama LB, Bourreille A, Dupas JL, Hébuterne X, Savoye G, Deplanque D, Bouhnik Y, Pelletier AL, Galtier F, Laharie D, Nachury M, Zerbib F, Allez M, Bommelaer G, Duclos B, Lucht F, Gougeon ML, Tartour E, Rozenberg F, Hanslik T, Beaugerie L, Carrat F; MICIVAX Study Group.

J Crohns Colitis. 2015 Dec;9(12):1096-107. doi: 10.1093/ecco-jcc/jjv152. Epub 2015 Sep 7.

PMID:
26351392
39.

Do Thiopurines Really Decrease the Risk of Colorectal Cancer in Ulcerative Colitis? The Light is Coming from Concept-based Subgroup Analyses.

Beaugerie L.

J Crohns Colitis. 2015 Dec;9(12):1061-2. doi: 10.1093/ecco-jcc/jjv155. Epub 2015 Sep 7. No abstract available.

PMID:
26351385
40.

Azathioprine induction of tumors with microsatellite instability: risk evaluation using a mouse model.

Bodo S, Svrcek M, Sourrouille I, Cuillières-Dartigues P, Ledent T, Dumont S, Dinard L, Lafitte P, Capel C, Collura A, Buhard O, Wanherdrick K, Chalastanis A, Penard-Lacronique V, Fabiani B, Fléjou JF, Brousse N, Beaugerie L, Duval A, Muleris M.

Oncotarget. 2015 Sep 22;6(28):24969-77. doi: 10.18632/oncotarget.4638.

41.

European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies.

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO.

J Crohns Colitis. 2015 Nov;9(11):945-65. doi: 10.1093/ecco-jcc/jjv141. Epub 2015 Aug 20. No abstract available.

42.

Cancers Complicating Inflammatory Bowel Disease.

Beaugerie L, Itzkowitz SH.

N Engl J Med. 2015 Jul 9;373(2):195. doi: 10.1056/NEJMc1505689. No abstract available.

PMID:
26154801
43.

Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures.

Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L, Amiot A, Altwegg R, Savoye G, Abitbol V, Bouguen G, Simon M, Duffas JP, Hébuterne X, Nancey S, Roblin X, Leteurtre E, Bommelaer G, Lefevre JH, Brunetti F, Guillon F, Bouhnik Y, Peyrin-Biroulet L.

Clin Gastroenterol Hepatol. 2015 Oct;13(10):1770-5. doi: 10.1016/j.cgh.2015.04.185. Epub 2015 May 19.

44.

Cancers complicating inflammatory bowel disease.

Beaugerie L, Itzkowitz SH.

N Engl J Med. 2015 Apr 9;372(15):1441-52. doi: 10.1056/NEJMra1403718. Review. No abstract available.

PMID:
25853748
45.

Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features.

Dohan A, Faraoun SA, Barral M, Guerrache Y, Boudiaf M, Dray X, Hoeffel C, Allez M, Farges O, Beaugerie L, Aparicio T, Marteau P, Fishman EK, Lucidarme O, Eveno C, Pocard M, Dautry R, Soyer P.

Diagn Interv Imaging. 2015 Sep;96(9):871-83. doi: 10.1016/j.diii.2015.02.009. Epub 2015 Apr 3. Review.

46.

[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version)].

van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO.

Rev Gastroenterol Mex. 2015 Jan-Mar;80(1):74-106. doi: 10.1016/j.rgmx.2014.10.008. Epub 2015 Mar 11. Spanish. No abstract available.

47.

Changes in the Lémann Index Values During the First Years of Crohn's Disease.

Gilletta C, Lewin M, Bourrier A, Nion-Larmurier I, Rajca S, Beaugerie L, Sokol H, Pariente B, Seksik P, Cosnes J.

Clin Gastroenterol Hepatol. 2015 Sep;13(9):1633-40.e3. doi: 10.1016/j.cgh.2015.02.041. Epub 2015 Mar 10.

PMID:
25766650
48.

[Non-digestive complications of inflammatory bowel diseases].

Beaugerie L.

Rev Prat. 2014 Nov;64(9):1230-1. Review. French. No abstract available.

PMID:
25638860
49.

[Natural history of intestinal lesions in inflammatory bowel disease].

Beaugerie L.

Rev Prat. 2014 Nov;64(9):1226-9. Review. French.

PMID:
25638859
50.

Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.

Gagniere C, Beaugerie L, Pariente B, Seksik P, Amiot A, Abitbol V, Allez M, Cosnes J, Sokol H.

J Crohns Colitis. 2015 Apr;9(4):349-55. doi: 10.1093/ecco-jcc/jju024. Epub 2014 Dec 28.

PMID:
25547977

Supplemental Content

Loading ...
Support Center